Mouth Ulcer Treatment Market Forecasts to 2030 – Global Analysis By Type (Minor, Major, Herpetiform and Other Types), Drug Class (Antimicrobial, Antihistamine, Analgesics, Corticosteroids and Other Drug Classes), Formulation (Sprays, Mouthwash, Gels, Loze

Mouth Ulcer Treatment Market Forecasts to 2030 – Global Analysis By Type (Minor, Major, Herpetiform and Other Types), Drug Class (Antimicrobial, Antihistamine, Analgesics, Corticosteroids and Other Drug Classes), Formulation (Sprays, Mouthwash, Gels, Lozenges and Other Formulations), Indication, Route of Administration, Distribution Channel, End User and by Geography

According to Stratistics MRC, the Global Mouth Ulcer Treatment Market is accounted for $1.59 billion in 2023 and is expected to reach $2.37 billion by 2030 growing at a CAGR of 5.9% during the forecast period. Mouth ulcers, commonly referred to as canker sores, are excruciating sores that may appear on the tongue, inside the cheeks, or on the lips. Although they usually go away on their own in a week or two, there are treatments that can help reduce discomfort and encourage quicker healing. Moreover, benzocaine or choline salicylate-containing over-the-counter topical ointments or gels can relieve pain. It might also be beneficial to rinse the mouth with a saltwater solution to lessen inflammation and encourage healing.

According to WHO 2020 report, in 2020, approximately 22.30% of the global population consumed tobacco products, and over 80% of the world's tobacco users live in low- and middle-income countries. Tobacco use can lead to mouth ulcers and thus the demand for treatment products increases.

Market Dynamics:

Driver:

Increasing knowledge and access to healthcare

An attitude shift toward seeking prompt medical attention for oral health issues, such as mouth ulcers, has resulted from increased awareness of oral health, which has been supported by educational campaigns and information dissemination. Individuals are more likely to address oral health concerns promptly when there is improved access to healthcare services, both in terms of physical infrastructure and telehealth options.

Restraint:

Absence of standardized guidelines for treatment

The lack of standardized and widely accepted treatment guidelines for mouth ulcers adds to the variation in medical procedures. Different approaches may be taken by clinicians, which make it difficult to establish standardized treatment protocols. Furthermore, this lack of standardization may make it more difficult for the industry to offer concise, scientifically supported mouth ulcer treatment options.

Opportunity:

Growing priority for comprehensive dental health

The market for mouth ulcer treatments has a chance to establish itself within the larger context of holistic oral care as people become more conscious of the link between oral health and general well-being. Moreover, preventive measures, dietary advice, and lifestyle suggestions can be incorporated into treatment plans to take advantage of this trend and promote a more thorough and patient-centered approach.

Threat:

Economic downturn and problems with affordability

Financial instability and economic downturns can affect how much consumers spend on medical supplies, such as mouth ulcer remedies. Financial difficulties can lead people to choose less expensive options or put off getting help. Additionally, market participants should investigate pricing strategies, patient assistance programs, and market access initiatives to ensure continued accessibility during times of economic instability in order to lessen the impact of economic challenges.

Covid-19 Impact

Due to disruptions in manufacturing, supply chains, and healthcare access, the COVID-19 pandemic has had a major effect on the market for mouth ulcer treatments. The diagnosis and treatment of mouth ulcers have been impacted by the decline in routine healthcare visits brought on by lockdowns, social distancing measures, and the increased healthcare priorities associated with the pandemic. Furthermore, the market's revenue streams may also be impacted by changes in consumer behaviour and economic uncertainty, which have an impact on buying patterns.

The Antimicrobial segment is expected to be the largest during the forecast period

The segment with the largest market share is the antimicrobial segment, due to their ability to prevent or treat bacterial and microbial infections, antimicrobial agents—such as topical antibiotics and antiseptics—are essential in the management of mouth ulcers. Due to their focused approach to treating the infectious aspect of mouth ulcers, accelerating healing, and reducing related symptoms, these treatments are frequently encouraged. Moreover, healthcare practitioners and consumers have a variety of options for effectively managing mouth ulcers thanks to the antimicrobial segment's wide range of topical formulations, which include gels, ointments, and mouthwashes.

The Homecare segment is expected to have the highest CAGR during the forecast period

In the mouth ulcer treatment market, the homecare segment is growing at the highest CAGR. The convenience of using over-the-counter mouth ulcer treatments at home, the growing popularity of self-administered treatments, and the development of telehealth services that enable remote consultations are some of the factors contributing to this growth. Additionally, growing awareness of oral health management and technological advancements that make it possible for people to obtain information and products for treating mouth ulcers without waiting for urgent clinical intervention are the main drivers of the shift towards homecare.

Region with largest share:

In the mouth ulcer treatment market, the Asia-Pacific area holds the largest market share. Numerous factors contribute to this dominance, such as the high frequency of mouth ulcers in the area, an aging population, rising oral health awareness, and pharmaceutical companies' persistent efforts to increase their footprint in emerging markets. Furthermore, the diverse healthcare landscape of the Asia-Pacific region, along with rising disposable incomes and improved healthcare infrastructure, has also contributed to the market's robust growth for mouth ulcer treatments.

Region with highest CAGR:

In the mouth ulcer treatment market, North America is currently showing the highest CAGR. A strong healthcare infrastructure, high healthcare spending, and a strong emphasis on research and development are some of the factors driving the region's robust growth. The aging population in the area, the increasing frequency of mouth ulcers, and the increased focus on oral health all add to the rising need for cutting-edge and efficient treatment options. Moreover, the market is expanding in North America due in part to the presence of major players in the industry, technological advancements, and a proactive approach to healthcare management.

Key players in the market

Some of the key players in Mouth Ulcer Treatment market include Celgene Corporation, 3M Company, GSK plc, Colgate-Palmolive Company, Blairex Laboratories, Inc., Dr. Reddy's Laboratories, Dental Herb Company, Bristol-Myers Squibb Company, GlaxoSmithKline, Plc, Patterson Companies, Inc., Pfizer, Inc., Akorn Pharmaceuticals, Church & Dwight Co, Inc., Prince Care Pharma Private Limited, Blistex Inc. and Sun Pharmaceutical Jsc.

Key Developments:

In December 2023, Dr Reddy's Laboratories on Wednesday said its unit has inked a licensing agreement with Coya Therapeutics Inc to develop a combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Dr Reddy's Laboratories SA and Coya have entered into a development and license agreement for the development and commercialisation of COYA 302, an investigational combination therapy for ALS, the Hyderabad-based drugmaker said in a statement.

In November 2023, GSK plc and Arrowhead Pharmaceuticals Inc. have announced that they have reached an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to transfer exclusive worldwide rights to further develop and commercialise JNJ-3989 to GSK. JNJ-3989 (formerly ARO-HBV) was initially in-licensed by Janssen from Arrowhead in 2018.



In May 2023, 3M announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A. (""Pierrel""), a global provider of services for the pharmaceutical industry, for a purchase price of $70 million, subject to closing and other adjustments.

Types Covered:
• Minor
• Major
• Herpetiform
• Other Types



Drug Classes Covered:
• Antimicrobial
• Antihistamine
• Analgesics
• Corticosteroids
• Other Drug Classes

Formulations Covered:
• Sprays
• Mouthwash
• Gels
• Lozenges
• Other Formulations

Indications Covered:
• Aphthous Stomatitis
• Oral Lichen Planus
• Other Indications



Route of Administrations Covered:
• Oral
• Topical

Distribution Channels Covered:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End Users Covered:
• Homecare
• Clinic
• Hospital
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants

- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends

- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements